Kidney Diseases Clinical Trial
Official title:
Best Case/Worst Case: A Multisite Randomized Clinical Trial of Scenario Planning for Patients With End-Stage Kidney Disease
Verified date | December 2023 |
Source | University of Wisconsin, Madison |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to test the effect of the "Best Case/Worse Case" (BC/WC) communication tool on receipt of palliative care and intensity of treatment at the end of life, quality of life, and quality of communication for older patients with end-stage renal disease (ESRD) receiving outpatient care at ten nephrology clinics. The intervention was developed and tested with acute care surgical patients at the University of Wisconsin (UW) and is now being testing to see if the intervention will work in a different setting. The intervention will be tested with 320 older adults who have end-stage renal disease (ESRD) and are receiving care from a nephrologist enrolled in the study. Randomly assigned nephrologists within each site will receive the intervention (training to use the BC/WC tool) or to be in the waitlist control, meaning that they will not be offered BC/WC training until the end of the study, when all participants have been enrolled. Participants will be on follow up with surveys and chart review for up to two years after study enrollment. Caregivers will also be invited to participate and complete surveys.
Status | Active, not recruiting |
Enrollment | 407 |
Est. completion date | January 2026 |
Est. primary completion date | January 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 60 Years and older |
Eligibility | Inclusion Criteria: - Estimated glomerular filtration rate (eGFR) of less than or equal to 24 - Not currently on dialysis (participants are eligible if they have had intermittent dialysis in the past or have dialysis access in place but are not currently on dialysis) - Participants must meet one or more of the following criteria: age greater than 80, evidence from the medical record that the patient has comorbid illness such that the modified Charlson score is 4 or greater, or a negative response to the standard "Surprise Question" ("Would you be surprised if this patient died in the next year?") from the participant's nephrologist. Exclusion Criteria: - Currently on dialysis - Lack decision-making capacity - Do not speak English |
Country | Name | City | State |
---|---|---|---|
United States | Johns Hopkins University | Baltimore | Maryland |
United States | Department of Medicine, University of Vermont | Burlington | Vermont |
United States | Northwestern University | Chicago | Illinois |
United States | University of Colorado, Denver | Denver | Colorado |
United States | Medical College of Wisconsin | Milwaukee | Wisconsin |
United States | West Virginia University | Morgantown | West Virginia |
United States | Columbia University | New York | New York |
United States | Mount Sinai School of Medicine | New York | New York |
United States | University of Pittsburgh | Pittsburgh | Pennsylvania |
United States | University of Washington | Seattle | Washington |
Lead Sponsor | Collaborator |
---|---|
University of Wisconsin, Madison | Columbia University, Icahn School of Medicine at Mount Sinai, Johns Hopkins University, Medical College of Wisconsin, National Institute on Aging (NIA), Northwestern University, The Palliative Care Research Cooperative Group, University of Colorado, Denver, University of Pittsburgh, University of Vermont, University of Washington, West Virginia University |
United States,
Ladin K, Lin N, Hahn E, Zhang G, Koch-Weser S, Weiner DE. Engagement in decision-making and patient satisfaction: a qualitative study of older patients' perceptions of dialysis initiation and modality decisions. Nephrol Dial Transplant. 2017 Aug 1;32(8):1394-1401. doi: 10.1093/ndt/gfw307. — View Citation
Schell JO, Patel UD, Steinhauser KE, Ammarell N, Tulsky JA. Discussions of the kidney disease trajectory by elderly patients and nephrologists: a qualitative study. Am J Kidney Dis. 2012 Apr;59(4):495-503. doi: 10.1053/j.ajkd.2011.11.023. Epub 2012 Jan 4. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Receipt of palliative care consult within 12 months of study enrollment, as determined by chart review or report by patient or caregiver | Number of patients with 1 or more palliative care consults within 12 months of study enrollment. | From enrollment up to 12 months | |
Secondary | Receipt of palliative care during 2-year follow up as determined by chart review or report by patient or caregiver | Number of patients with receipt of any palliative care as determined by chart review or patient or caregiver report during 2-year follow up. | From enrollment for up to 2 years | |
Secondary | Patient-reported health-related quality of life | Patient-reported health related quality of life will be measured using the 46-item Functional Assessment of Chronic Illness Therapy-Palliative Care Version 4 (FACIT-Pal); the investigators will compare the average score and average change (slope) in health-related quality of life over time, using the total score at last follow up. Possible scores for the FACIT-Pal total score range from 0-184. Higher scores indicate better quality of life. | Every 3 months for up to 2 years after enrollment | |
Secondary | Patient-reported health-related quality of life | Patient-reported health related quality of life will be measured using the 27-item Functional Assessment of Cancer Therapy - General (FACT-G) scale (used here in non-cancer patients as part of the FACIT-Pal instrument). Possible scores for the FACT-G total score range from 0-108. Higher scores indicate better quality of life. | Every 3 months for up to 2 years after enrollment | |
Secondary | Patient-reported health-related quality of life | Patient-reported health related quality of life will be measured using the 19-item FACIT-Pal palliative care subscale (PalS). Possible scores for the PalS range from 0-76. Higher scores indicate better quality of life. | Every 3 months for up to 2 years after enrollment | |
Secondary | Patient-reported quality of communication (QOC) received from study nephrologist | Patient-reported general quality of communication will be measured using the 19-item Quality of Communication (QOC) scale. The QOC is a validated self-report instrument. The average composite score will be given with a possible range of 0-10. Higher scores indicate higher perceived quality of communication. | 48 hours after enrollment | |
Secondary | Patient-reported general quality of communication (QOC) received from study nephrologist | Patient-reported general quality of communication will be measured using the 6-item general communication subscale of the 19-item Quality of Communication (QOC) scale. The QOC is a validated self-report instrument. The average item score will be given with a possible range of 0-10. Higher scores indicate higher perceived quality of communication. | 48 hours after enrollment | |
Secondary | Patient-reported quality of end-of-life communication (QOC) received from study nephrologist | Patient-reported quality of end-of-life communication will be measured using 7-item end-of-life communication subscale of the 19-item Quality of Communication scale. The QOC is a validated self-report instrument. The average item score will be given with a possible range of 0-10. Higher scores indicate higher perceived quality of communication. | 48 hours after enrollment | |
Secondary | Hospice enrollment during 2-year follow up as determined by chart review or report by patient or caregiver | Number of patients with documentation of hospice enrollment as determined by chart review and patient or caregiver report during 2-year follow up. | From enrollment for up to 2 years | |
Secondary | Documentation of new advance care planning during 2-year follow up as determined by chart review or report by patient or caregiver | Number of patients with new documentation of advance care planning as determined by chart review or patient or caregiver report during 2-year follow up. | From enrollment for up to 2 years | |
Secondary | Treatment intensity at the end of life review as determined by chart review or report by patient or caregiver | Number of patients with one or more of the following within 30 days of death: ER visit, ICU stay or hospitalization as determined by chart review or patient or caregiver report. | Within 30 days of death | |
Secondary | Surgical treatment intensity at the end of life as determined by chart review or report by patient or caregiver | Number of patients who had one or more surgical procedure within 30 day as determined by chart review or patient or caregiver report. | Within 30 days of death | |
Secondary | Initiation of dialysis as determined by chart review or report by patient or caregiver | Number of patients initiating dialysis as determined by chart review or patient or caregiver report. | From enrollment for up to 2 years | |
Secondary | Time to on-study death | Time, in six month intervals, from baseline to 2 years. The Kaplan-Meier estimate reports the percentage of participants who experience death within 2 years from randomization. Participant death will be ascertained through medical record review and caregiver report. | From enrollment for up to 2 years | |
Secondary | Caregiver-reported quality of dying and death | Quality of dying and death as perceived by the patient's caregiver will be measured using the Quality of Death and Dying (QODD) survey that asks about the patient's final 30 days of life. Possible scores on this measure range from 0 to 100 and higher scores indicate higher quality of dying and death. | 3 months after death | |
Secondary | Caregiver-reported health related quality of life | Caregiver-reported health related quality of life will be measured using the Cambridge Palliative Audit Schedule (CAMPAS-R). Possible scores on this survey range from 0-100 and higher scores indicate greater symptomology. | Every 3 months for up to 2 years after enrollment | |
Secondary | Caregiver-reported general quality of communication (QOC) received from study nephrologist | Caregiver-reported general quality of communication will be measured using the 6-item general communication subscale of the 19-item Quality of Communication (QOC) scale. The QOC is a validated self-report instrument. Possible scores on this subscale range from 0-60. Higher scores indicate higher perceived quality of communication. | Within 48 hours after enrollment | |
Secondary | Caregiver-reported quality of end-of-life communication (QOC) received from study nephrologist | Caregiver-reported quality of end-of-life communication will be measured using 7-item end-of-life communication subscale of the 19-item Quality of Communication scale. The QOC is a validated self-report instrument. Possible scores on this subscale range from 0-70. Higher scores indicate higher perceived quality of communication. | Within 48 hours after enrollment | |
Secondary | Treatment intensity at the end of life as determined by chart review or report by patient or caregiver | Number of patients with 1 or more ICU admission within 30 days of death. | Within 30 days before death |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03246984 -
VALUE- Vascular Access Laminate eUropean Experience. A Post Market Surveillance Study to Assess the Safety and Effectiveness of VasQ
|
N/A | |
Completed |
NCT03545113 -
Graft-first Versus Fistula-first in Older Patients With End-stage Kidney Disease
|
N/A | |
Recruiting |
NCT05100017 -
Methocarbamol vs Oxybutynin for Management of Pain and Discomfort S/P Ureteroscopy Procedure
|
N/A | |
Recruiting |
NCT04559321 -
Holmium Vs Trilogy Kidney Stones GUY's 1-2
|
Phase 3 | |
Recruiting |
NCT05036850 -
China Kidney Patient Trials Network
|
||
Completed |
NCT04037436 -
Functional Exercise and Nutrition Education Program for Older Adults
|
N/A | |
Active, not recruiting |
NCT01529658 -
Renal Hypothermia During Partial Nephrectomy
|
N/A | |
Completed |
NCT01679587 -
Dose Escalation Study to Investigate Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BAY85-3934 in Subjects With Chronic Kidney Disease (CKD)
|
Phase 1 | |
Completed |
NCT01155141 -
Idiopathic Focal Segmental Glomerulosclerosis (FSGS) and Treatment With ACTH
|
Phase 4 | |
Completed |
NCT00755690 -
Study of Dietary Phosphate and Mineral Homeostasis in Early Chronic Kidney Disease
|
N/A | |
Recruiting |
NCT05759754 -
Effects of Traditional Chinese Medicine (GSJYF) in Children With Inherited Proteinuric Kidney Disease
|
N/A | |
Completed |
NCT03213158 -
Ixazomib for Desensitization
|
Phase 2 | |
Active, not recruiting |
NCT02237352 -
Mechanisms of Diabetic Nephropathy in Ecuador
|
||
Recruiting |
NCT06067867 -
Kidney and Pregnancy Registry
|
||
Recruiting |
NCT04110080 -
Enhanced Recovery After Surgery in Kidney Transplant Donors
|
N/A | |
Active, not recruiting |
NCT04876963 -
HOLT-ED: Holter-monitoring in End-stage Renal Disease
|
||
Enrolling by invitation |
NCT05324878 -
Honoring Individual Goals and Hopes: Implementing Advance Care Planning for Persons With Kidney Disease on Dialysis
|
||
Not yet recruiting |
NCT03899298 -
Safety and Clinical Outcomes With Amniotic and Umbilical Cord Tissue Therapy for Numerous Medical Conditions
|
Phase 1 | |
Active, not recruiting |
NCT04631965 -
Healthcare Transition of Adolescents With Chronic Health Conditions
|
||
Completed |
NCT03394859 -
Electronic Medical Records and Genomics (eMERGE) Phase III
|